[go: up one dir, main page]

EP0487593A1 - Composes macrocycliques - Google Patents

Composes macrocycliques

Info

Publication number
EP0487593A1
EP0487593A1 EP90912790A EP90912790A EP0487593A1 EP 0487593 A1 EP0487593 A1 EP 0487593A1 EP 90912790 A EP90912790 A EP 90912790A EP 90912790 A EP90912790 A EP 90912790A EP 0487593 A1 EP0487593 A1 EP 0487593A1
Authority
EP
European Patent Office
Prior art keywords
dioxa
tetramethyl
compound
dimethoxy
trione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90912790A
Other languages
German (de)
English (en)
Inventor
David Keith Donald
David Norman Hardern
Martin Edward Cooper
Mark Furber
Masashi Hashimoto
Chiyoshi Kasahara
Takehiko Ohkawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisons Ltd
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fisons Ltd
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898918927A external-priority patent/GB8918927D0/en
Priority claimed from GB898922653A external-priority patent/GB8922653D0/en
Priority claimed from GB909012426A external-priority patent/GB9012426D0/en
Application filed by Fisons Ltd, Fujisawa Pharmaceutical Co Ltd filed Critical Fisons Ltd
Publication of EP0487593A1 publication Critical patent/EP0487593A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Definitions

  • This invention relates to novel macrocyclic compounds, more particularly to novel macrocyclic immunosuppressive compounds, processes for their preparation, their use as 5 medicaments, and compositions containing them.
  • European Patent Application 184162 discloses a number of macrocyclic compounds isolated from microorganisms belonging to the genus Streptomvces.
  • the macrolides are numbered FR-900506, 0 FR-900520, FR-900523 and FR-900525, and the preparation of some of their derivatives is also described.
  • R 1 represents H, OH, alkoxy or R 7 COO-;
  • R 2 represents H; in addition, R 1 and R 2 may together represent a second carbon-carbon bond between the carbon atoms to which they are attached;
  • R 3 represents methyl, ethyl, propyl or allyl
  • R 4 represents OH or alkoxy
  • R 5 represents OH or methoxy
  • R 6 represents OH, alkoxy or R 8 COO-; in which R 7 and R 8 independently represent alkyl; aryl; NH 2 ; a 5- or 6-membered heterocyclic ring optionally substituted by alkyl or aryl; arylamino; alkylamino; N,N-dialkylamino; N,N-diarylamino; or N-alkyl-N-arylamino; each alkyl group optionally being substituted by aryl, OH, N0 2 or halogen; and each aryl group optionally being substituted by alkyl, OH, N0 2 or halogen; and n represents 1 or 2; provided that when n is 1, then R 3 is allyl or propyl.
  • R , R 5 and R 6 represents a carbon containing group, that group preferably contains from 1 to 10 carbon atoms, more preferably from 1 to 6.
  • alkyl as used herein includes cyclic and branched alkyl groups, as well as straight chain alkyl groups.
  • R 3 is ethyl.
  • R 1 and R 6 we prefer at least one of R 1 and R 6 to represent OH.
  • R 7 or R 8 we prefer those groups to be selected from alkyl; NH 2 ; piperidino; morpholino; aryl optionally substituted by halogen or OH; arylamino optionally substituted by halogen or OH; or alkylamino optionally substituted by OH; for example methyl or phenylamino.
  • Alkoxy groups which R 1 , R 4 or R 6 may represent Q include methoxy.
  • Aryl groups which R 7 or R 8 may comprise include phenyl.
  • R 1 to R and n are as defined above, or b) addition of a compound of formula R 4 -H, wherein R 4 is as defined above, across the Cl alkene group in a compound of formula III,
  • the reduction may be achieved by the action of H 2 S, preferably in the presence of pyridine or an amine (for example morpholine) , in a solvent which does not adversely affect the reaction (for example dimethylformamide, pyridine or methanol) , at or around room temperature.
  • a solvent which does not adversely affect the reaction for example dimethylformamide, pyridine or methanol
  • the addition of water across the Cl-alkene group may be achieved by the action of dilute agueous acid (for example dilute hydrochloric acid) , in a solvent which does not adversely affect the reaction (for example water, methanol, ethanol, pyridine, ethyl acetate, dimethylformamide, dichloromethane or a mixture thereof) , at or around room temperature.
  • dilute agueous acid for example dilute hydrochloric acid
  • a solvent which does not adversely affect the reaction for example water, methanol, ethanol, pyridine, ethyl acetate, dimethylformamide, dichloromethane or a mixture thereof
  • the addition of an alcohol may be achieved in the presence of a small amount of acid
  • a solvent which does not adversely affect the reaction for example the alcohol to be added, pyridine, ethyl acetate, dimethylformamide, dichloromethane or a mixture thereof, at or around room temperature.
  • R 1 to R 3 , R 5 , and n are as defined above, by reduction, which may be achieved using tributyltin hydride, preferably in the presence of a catalytic amount of 2,2'-azobisisobutyronitrile, in a solvent which does not adversely affect the reaction conditions, for example anhydrous toluene, at a temperature of from room temperature to solvent reflux temperature.
  • R 1 to R 3 , R 5 , R 6 and n are as defined above, by reaction with O-phenyl chlorothioformate, in a solvent which does not adversely affect the reaction (for example acetonitrile) , optionally in the presence of dimethylaminopyridine, at or around room temperature.
  • a solvent which does not adversely affect the reaction for example acetonitrile
  • Compounds of formula V may be prepared from compounds of formula II, as defined above, by reduction.
  • the reduction may be achieved using zinc powder in acetic acid at or around room temperature.
  • R 6 represents or comprises an OH group in the desired compound of formula I
  • the group R 8 COO- may be formed in a starting compound of formula II in which R 6 represents OH using conventional techniques, for example: i) when R 8 represents alkyl or aryl, an esterification reaction with an appropriate alkanoic acid or aromatic carboxylic acid may be employed, or a derivative thereof such as an acid chloride or acid anhydride; ii) when R 8 represents alkylamino or arylamino, reaction with an appropriate alkyl or aryl isocyanate; alternatively a reactive intermediate may first be formed with a compound such as p-nitrophenyl chloroformate, followed by reaction with the appropriate amine compound. This latter method may be employed when R 8 is NH 2 .
  • R 7 COO- groups may be formed in a starting compound of formula II in which R 1 represents OH. This reaction may occur simultaneously with the formation of R 8 COO- groups as described above, in which case R 7 and R 8 will be the same.
  • the OH group that R 1 or R 6 represents may be protected using conventional protecting group chemistry [as described in "Protective Groups in Organic Chemistry", ed: J W F McOmie, Plenum Press (1973) , and “Protective Groups in Organic Synthesis", T W Greene, Wiley-Interscience (1981)], to ensure that R 7 and R 8 are different, or to allow one or other of R 1 and R 6 to be deprotected to OH after formation of the C2-methylene group or formation of the R 7 COO- or R 8 COO- group.
  • R 7 COO- or R 8 COO- groups may be introduced before or after the reduction step.
  • the double bond may be introduced by dehydration of a corresponding compound of formula I in which R 1 represents OH and R 2 represents H, or a starting com ⁇ und may be used which already contains the group.
  • a dehydration may be carried out in a solvent which does not adversely affect the reaction (eg toluene) , in the presence of a trace amount of acid (eg p-toluenesulphonic acid) , at a temperature of from 50 to 100 ⁇ C.
  • the compounds of formula I may be isolated from their reaction mixtures using conventional techniques.
  • the compounds of formula I are useful because they possess pharmacological activity in animals; in particular they are useful because they possess immunosuppressive activity, eg in the tests set out in Tests A, B and C.
  • the compounds are indicated for use in the treatment or prevention of resistance to transplanted organs or tissues, such as kidney, heart, lung, bone marrow, skin, cornea, etc; and of autoimmune, inflammatory, proliferative and hyperproliferative diseases, and of cutaneous manifestations of immunologically-mediated diseases: for example rheumatoid arthritis, lupus erythematosus, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type 1 diabetes, uveitis, nephrotic syndrome, psoriasis, atopical dermatitis, contact dermatitis and further eczematous dermatitides, seborrheic dermatitis.
  • Lichen planus Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias. Alopecia areata , etc .
  • the compounds of the invention are also indicated in the treatment of reversible obstructive airways disease.
  • the compounds of the invention are indicated in the treatment of a disease selected from intestinal inflammations/allergies such as Coeliac disease, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease and ulcerative colitis; and food related allergic diseases which have symptomatic manifestation remote from the gastro-intestinal tract, for example migraine, rhinitis and eczema.
  • a disease selected from intestinal inflammations/allergies such as Coeliac disease, proctitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease and ulcerative colitis
  • food related allergic diseases which have symptomatic manifestation remote from the gastro-intestinal tract, for example migraine, rhinitis and eczema.
  • the compounds of the invention are also indicated for use as antimicrobial agents, and thus may be used in the treatment of diseases caused by pathogenic microorganisms and the like.
  • the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired (eg topical, parenteral or oral) and the disease indicated. However, in general, satisfactory results are obtained when the compounds are administered at a daily dosage of from 0.001 to 20mg per kg of animal body weight.
  • unit dosage forms suitable for administration comprise from O.Olmg to 500mg, and preferably 0.5mg to lOOmg of the compound preferably admixed with a solid or liquid pharmaceutically acceptable diluent, carrier or adjuvant.
  • a pharmaceutical composition comprising preferably less than 80%, and more preferably less than 50% by weight, of a compound of fomula I in combination with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • suitable adjuvants, diluents or carriers are: for tablets, capsules and dragees - microcrystalline cellulose, calcium phosphate, diatomaceous earth, a sugar such as lactose, dextrose or mannitol, talc, stearic acid, starch, sodium bicarbonate and/or gelatin; for suppositories - natural or hardened oils or waxes; and for inhalation compositions - coarse lactose.
  • the compound of formula I preferably is in a form having a mass median diameter of from 0.01 to 10 / xm.
  • the compositions may also contain suitable preserving, stabilising and wetting agents, solubilisers (eg a water-soluble cellulose polymer such as hydroxypropyl methylcellulose, or a water-soluble glycol such as propylene glycol) , sweetening and colouring agents and flavourings.
  • solubilisers eg a water-soluble cellulose polymer such as hydroxypropyl methylcellulose, or a water-soluble glycol such as propylene glycol
  • sweetening and colouring agents and flavourings eg. a water-soluble cellulose polymer such as hydroxypropyl methylcellulose, or a water-soluble glycol such as propylene glycol
  • sweetening and colouring agents and flavourings eg. a water-soluble cellulose polymer such as hydroxypropyl methylcellulose, or a water-soluble glycol such as propylene
  • the compounds of formula I have the advantage that they are less toxic, more efficacious, are longer acting, have a broader range of activity, are more potent, are more stable, produce fewer side effects, are more easily absorbed or have other useful pharmacological properties, than compounds previously used in the therapeutic fields mentioned above.
  • the compounds of formula I have a number of chiral centres and may exist in a variety of stereoisomers.
  • the invention provides all optical and stereoisomers, as well as racemic mixtures.
  • the isomers may be resolved or separated by conventional techniques.
  • the MLR test was performed in microtitre plates, with each well containing 5 x 10 5 C57BL/6 responder cells (H-2 b ) , 5 x 10 5 mitomycin C treated (25 ⁇ g/ml mitomycin C at 37 ⁇ C for 30 minutes and washed three times with RPMI 1640 medium) BALB/C stimulator cells (H-2 d ) in 0.2ml RPMI 1640 medium supplemented with 10% fetal calf serum, 2mM sodium hydrogen carbonate, penicillin (50 / _g/ml) and streptomycin (50 ⁇ g/ml) .
  • the cells were incubated at 37 ⁇ C in a humidified atmosphere of 5% carbon dioxide and 95% of air for 68 hours and pulsed with 3 H-thymidine (0.5 ⁇ Ci) 4 hours before the cells were collected.
  • the object compound of this invention was dissolved in ethanol and further diluted in RPMI 1640 medium and added to the cultures to give final concentrations of O.l ⁇ g/ml or less.
  • MLR Mixed Lymphocyte Reaction fMLR II
  • the MLR test was performed in 96-well microtitre plates with each well containing 3 x 10 5 cells from each of two responding donors in a final volume of 0.2ml RPMI 1640 medium supplemented with 10% human serum, L-glutamine and penicillin/streptomycin.
  • the compound under test was dissolved at lOmg/ml in ethanol and further diluted in RPMI 1640.
  • the cells were incubated at 37 ⁇ C in a humidified atmosphere at 5% carbon dioxide for 96 hours. 3H-thymidine (O. ⁇ Ci) was added for the final 24 hours of the incubation to provide a measure of proliferation.
  • Spleen cells from DA and DAxLewis Fl hybrid rats were prepared at approximately 10 8 cells/ml. 0.1ml of these suspensions were injected into the rear footpads of DAxLewis Fl rats (left and right respectively) . Recipient animals aere dosed with the compound under test, either orally or subcutaneously, on days 0-4. The assay is terminated on day 7 when the popliteal lymph nodes of the animals are removed and weighed. The increase in weight of the left node relative to the wieght of the right is a measure of the GVH response.
  • Example l The invention is illustrated, but in no way limited by, the following Examples.
  • Example l The invention is illustrated, but in no way limited by, the following Examples.
  • step (c) The product of step (c) (lOOmg) was dissolved in a mixture of IN aqueous hydrochloric acid (0.2ml) and methanol (0.5ml). The solution was allowed to stand at ambient temperature for 16 hours and then the solvent was removed under reduced pressure and the residue purified by flash chromatography on silica gel eluting with ethyl acetate/hexane [1:2] to give the title compound (67mg) .
  • Example 1(d) Similarly, the title compound was also prepared from the (1Z)-compound of step (c) .
  • Example 1(c) To a solution of the product of Example 1(c) (80mg) in anhydrous methanol (lml) was added a 0.1M solution of p-toluenesulphonic acid monohydrate in methanol (0.25ml).
  • the subtitle compound (263mg) was obtained from the product of step (a) (900mg) .
  • the subtitle compound (156mg) was obtained from the product of step (b) (233 mg) .
  • the subtitle compound (1.59g) was prepared from 17-allyl-l- hydroxy-12-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylvinyl] -23,25-dimethoxy-13,19,21,27-tetramethyl-ll,28-di ⁇ xa-4- azatricyclo[22.3.1.0 4 * 9 ]octacosa-14,18-diene-2,3,10,16- tetraone (the second compound of Example 17, EP 184162) (2.0g) and morpholine following the method of Example 7(a).
  • the subtitle compound (1.59g) was prepared from the product of step (a) (1.59g) following the method of Example 1(a).
  • the subtitle compound (0.771g) was obtained from the product of step (b) following the method of Example 1(b).
  • Example 1(d) Similarly, the title compound was also prepared from the (1Z)-compound.
  • Hydrogen sulphide gas was bubbled through a solution of 17-allyl-l,14-dihydroxy-12-[2-(3,4-dihydroxycyclohexyl)-1- methylvinyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-ll,28- dioxa-4-azatricyclo[22.3.1.0 4 ' 9 ]octacos-18-ene-2,3,10,16- 5 tetraone (FR-901154, EP 353678) (40mg) in pyridine (2ml) and dimethylformamide (0.1ml) for 2 hours at room temperature.
  • Example 1 The compound of Example 1 was tested according to Test A above, and found to suppress the mixed lymphocyte reaction by 50% (IC 50 ) at a concentration of 2.4xlO ⁇ 8 M.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Des composés répondant à la formule (I) sont décrits, où R1 représente H, OH, de l'alkoxy ou du R7COO-; R2 représente H; de plus, R1 et R2 peuvent ensemble représenter une deuxième liaison carbone-carbone entre les atomes de carbone auxquels ils sont fixés; R3 représente du méthyle, de l'éthyle, du propyle ou de l'allyle; R4 représente OH ou de l'alkoxy; R5 représente OH ou du méthoxy; R6 représente OH, de l'alkoxy ou du R8COO-; R7 et R8 ont de nombreuses significations comprenant de l'alkyle, de l'aryle, du NH2, de l'arylamino et de l'alkylamino; enfin, n représente 1 ou 2, à condition que lorsque n est égal à 1, R3 soit l'allyle ou le propyle. Sont également décrits des procédés de fabrication pour des compositions les renfermant, afin d'être utilisées comme agents d'immunosuppression.
EP90912790A 1989-08-18 1990-08-10 Composes macrocycliques Withdrawn EP0487593A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB8918927 1989-08-18
GB898918927A GB8918927D0 (en) 1989-08-18 1989-08-18 Compounds
GB8922653 1989-10-09
GB898922653A GB8922653D0 (en) 1989-10-09 1989-10-09 Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same
GB9012426 1990-06-04
GB909012426A GB9012426D0 (en) 1990-06-04 1990-06-04 Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same

Publications (1)

Publication Number Publication Date
EP0487593A1 true EP0487593A1 (fr) 1992-06-03

Family

ID=27264646

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90912790A Withdrawn EP0487593A1 (fr) 1989-08-18 1990-08-10 Composes macrocycliques

Country Status (9)

Country Link
EP (1) EP0487593A1 (fr)
JP (1) JPH05504944A (fr)
CN (1) CN1049503A (fr)
AU (1) AU6286690A (fr)
GR (1) GR900100614A (fr)
IE (1) IE902995A1 (fr)
IL (1) IL95385A0 (fr)
PT (1) PT95039A (fr)
WO (1) WO1991002736A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04500372A (ja) * 1989-06-14 1992-01-23 サンド・リミテッド 異種原子含有三環式化合物
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
MY110418A (en) * 1990-07-02 1998-05-30 Novartis Ag Heteroatoms-containing tricyclic compounds.
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5494820A (en) * 1991-04-11 1996-02-27 Pfizer Inc. Streptomyces braegensis strain and its cultivation in a process for producing C9 -desoxo-FK-520
FI921595L (fi) * 1991-04-17 1992-10-18 American Home Prod Rapamycinkarbamater
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5250678A (en) * 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
DE69232630T2 (de) * 1991-09-05 2003-10-09 Abbott Laboratories, Abbott Park Makrocyclische immunmodulatoren
US5534632A (en) * 1991-09-05 1996-07-09 Abbott Laboratories Macrocyclic carbamate immunomodulators
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
GB9125660D0 (en) * 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
US5612316A (en) * 1992-03-02 1997-03-18 Pfizer Inc. Fluorosugar derivatives of macrolides
CA2131373C (fr) * 1992-03-02 1999-01-26 Kevin Koch 2-aminoglycomacrolides
ES2102642T3 (es) * 1992-03-02 1997-08-01 Pfizer Derivados azucares de macrolidos.
PT629203E (pt) * 1992-03-02 2002-01-30 Pfizer Derivados desoamino de macrolidos como agentes imunosupressores e antifungicos
CA2091194A1 (fr) * 1992-04-08 1993-10-09 Richard D. Connell Derives 2-oxoethyliques utilises comme immunosuppresseurs
US5284840A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
CA2106034A1 (fr) * 1992-09-24 1994-03-25 Ralph J. Russo La 21-norrapamycine
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
US7186518B2 (en) * 2003-11-21 2007-03-06 Dade Behring Inc. Method and composition useful for determining FK 506
EP1768662A2 (fr) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
KR102109168B1 (ko) * 2018-12-11 2020-05-12 인트론바이오테크놀로지 신규 화합물 및 이를 포함하는 진균감염 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
ATE120466T1 (de) * 1987-12-09 1995-04-15 Fisons Plc Makrozyklische verbindungen.
US4981792A (en) * 1988-06-29 1991-01-01 Merck & Co., Inc. Immunosuppressant compound
DE68921934T2 (de) * 1988-06-29 1995-10-19 Merck & Co Inc Immunsuppressives Agens.
DE68925080T2 (de) * 1988-08-01 1996-05-15 Fujisawa Pharmaceutical Co FR-901154- und FR-901155-Derivate, Verfahren zu ihrer Herstellung
EP0356399A3 (fr) * 1988-08-26 1991-03-20 Sandoz Ag Dérivés substitués du 4-azatricyclo (22.3.1.04.9) octacos-18-ène, leur préparation et les compositions pharmaceutiques les contenant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9102736A1 *

Also Published As

Publication number Publication date
IE902995A1 (en) 1991-02-27
IL95385A0 (en) 1991-06-30
JPH05504944A (ja) 1993-07-29
GR900100614A (el) 1991-12-30
CN1049503A (zh) 1991-02-27
PT95039A (pt) 1991-04-18
WO1991002736A1 (fr) 1991-03-07
AU6286690A (en) 1991-04-03

Similar Documents

Publication Publication Date Title
EP0487593A1 (fr) Composes macrocycliques
EP0594600A1 (fr) Composes macrocycliques immunosuppresseurs
FI90550B (fi) Menetelmä valmistaa terapeuttisesti aktiivista makrosyklistä johdannaista
US5912253A (en) Rapamycin derivatives
US5457194A (en) Substituted aliphatic amine-containing macrocyclic immunomodulators
US5179087A (en) Macrocyclic compounds
WO1991013899A1 (fr) Composes tricyclo
IE69974B1 (en) Heteroatoms-containing tricyclic compounds
PL172789B1 (pl) Sposób wytwarzania nowych makrolidów imidazolilowych PL PL PL
WO1994021635A1 (fr) Immunomodulateurs macrocycliques
JPH05163280A (ja) 二環式ラパマイシン
EP0629203B1 (fr) Derives de desosamino de macrolides utiles comme immunosuppresseurs et antifongiques
EP0626385B1 (fr) Dérivés de tétrahydropyrane
US5384316A (en) 4,16-diazatetracyclo[23.3.1.1.Hu 14,17=b . 0 Hu 4,9 triaconta-16,19-diene-2,3,10-trione derivatives
WO1994021253A1 (fr) Immunomodulateurs macrocycliques substitues contenant des amines aliphatiques
CA2156065A1 (fr) Immunomodulateurs a base d'uree et d'amide macrocyclique
US5210227A (en) Immunosuppressive compounds
US6121257A (en) Sulfamate containing macrocyclic immunomodulators
US5296489A (en) Immunosuppressive macrocyclic compounds
US5561139A (en) Substituted alicyclic-aliphatic amine-containing macrocyclic immunomodulators
JPH0774220B2 (ja) 新規な水酸化物媒介ｆｋ―５０６転位生成物
WO1993016083A1 (fr) Composes macrocycliques et utilisation de ces derniers en tant que produits pharmaceutiques
JPH05239064A (ja) 半合成免疫抑制マクロライド
JPH07500352A (ja) マクロライドの糖誘導体
WO1994005685A1 (fr) Composes macrocycliques utilises en therapie

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19940419

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940630